Business
IceCure Showcases ProSense® Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. Market
IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced its participation in the American Society of Breast Surgeons ("ASBrS") 2026 Annual Meeting, in Seattle from April 29 to May 3, 2026, where it exhibited ProSense® and sponsored a breakfast symposium titled "Unlocking De-Escalation: Cryoablation for Breast Cancer." The sy
About this update from Icecure Medical Ltd.
[{"type":"text","content":"As the only FDA cleared minimally invasive treatment option for low-risk breast cancer, ProSense® is aligned with the trend toward de-escalation of breast cancer treatment—a key theme at this year's meeting ","length":210,"tagName":"p","attribs":{}},{"type":"text","content":"American Society of Breast Surgeons (ASBrS) recently recommend cryoablation for low-risk breast cancer in its updated Resource Guide","length":132,"tagName":"p","attribs":{}},{"type":"text","content":"IceCure sponsored a cryoablation symposium led by Key Opinion Leader breast physicians from leading medical institutions including Cleveland Clinic, University of Michigan, West Cancer Center, and the Warren Alpert Medical School of Brown University who shared their thoughts about and their experience using ProSense®","length":318,"tagName":"p","attribs":{}},{"type":"text","content":"Company expects to report U.S. revenue of ProSense® systems and cryoprobes increased more than 30% in the first quarter of 2026 compared the same period last year, based on preliminary, unaudited estimates","length":205,"tagName":"p","attribs":{}},{"type":"text","content":"CAESAREA, Israel, May 5, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced its participation in the American Society of Breast Surgeons ("ASBrS") 2026 Annual Meeting, in Seattle from April 29 to May 3, 2026, where it exhibited ProSense® and sponsored a breakfast symposium titled "Unlocking De-Escalation: Cryoablation for Breast Cancer." The symposium highlighted the growing clinical adoption of cryoablation as a minimally invasive option for the treatment of low-risk breast cancer, an indication for which ProSense® received the U.S. Food and Drug Administration's ("FDA") marketing clearance in October 2025.","length":884,"tagName":"p"},{"type":"image","alt":"IceCure Medical Logo","displaySize":"","headline":null,"caption":"IceCure Medical Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":200,"url":"https://media.zenfs.com/en/prnewswire.com/b733b9648e0c5c7b36e9d5bf48d042cc"},"resized":{"url":"https://s.yim...